Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Not approvable letter for proposed Angiomax label amendment

June 8, 2004

Merck KGaA patent covers new factor Xa and factor VIIa inhibitors

June 3, 2004

Six months additional exclusivity for Agrylin

June 2, 2004

Argatroban pharmacokinetics studied in hemodialysis patients

May 24, 2004

Novel factor Xa inhibitors covered by BMS patent

May 21, 2004

Novel factor Xa inhibitor with potent anticoagulant and antithrombotic activity

May 19, 2004

Inflazyme discontinues further development of GH-9001

May 18, 2004

TTP-889 successfully completes phase I

May 13, 2004

Exanta completes E.U. mutual recognition procedure

May 12, 2004

Japanese team presents hemoglobin-derived plasmin modulators

May 7, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.